Kiniksa Pharmaceuticals Files Form 4 on April 8, 2026
Ticker: KNSA · Form: 4 · Filed: Apr 8, 2026 · CIK: 0001730430
Sentiment: neutral
Topics: insider-filing, ownership-change
TL;DR
Kiniksa Pharma filed a Form 4 on 4/8/26 for ownership changes on 4/6/26.
AI Summary
On April 8, 2026, Kiniksa Pharmaceuticals International, plc filed a Form 4, reporting changes in beneficial ownership of securities. The report covers transactions that occurred on April 6, 2026. Specific details regarding the nature of the transactions, the number of shares, and the individuals involved are not provided in this summary document.
Why It Matters
Form 4 filings are crucial for investors as they disclose changes in stock ownership by company insiders, providing insights into their confidence in the company's performance.
Risk Assessment
Risk Level: low — This filing is a standard disclosure of ownership changes by insiders and does not inherently indicate positive or negative company performance.
Key Players & Entities
- Kiniksa Pharmaceuticals International, plc (company) — Issuer
- 0001730430 (company) — Issuer CIK
- 0001384243-26-000008 (filing_id) — SEC Accession Number
- 2026-04-08 (date) — Filing Date
- 2026-04-06 (date) — Period of Report
FAQ
What is the SEC Accession Number for this filing?
The SEC Accession Number is 0001384243-26-000008.
What is the filing date of this Form 4?
The filing date is 2026-04-08.
What period does this report cover?
The period of report is 2026-04-06.
What is the CIK number for Kiniksa Pharmaceuticals International, plc?
The CIK number for Kiniksa Pharmaceuticals International, plc is 0001730430.
What is the primary business of Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals is in the Pharmaceutical Preparations industry (SIC 2834).
Filing Details
This Statement of Changes in Beneficial Ownership (Form 4) was filed with the SEC on April 8, 2026 regarding Kiniksa Pharmaceuticals International, plc (KNSA). Form 4 filings disclose purchases, sales, or other changes in ownership by company insiders such as officers, directors, and major shareholders.